<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Many investigators have been intrigued by the paradoxical association of a circulating <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, first called <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> by Feinstein and Rapaport [1], with a tendency to develop <z:mp ids='MP_0005048'>thrombosis</z:mp>, as initially described by Walter Bowie [2] </plain></SENT>
<SENT sid="1" pm="."><plain>Work in Leuven on this topic started when Luis Carreras, an Argentinian hematologist, joined the laboratory of blood coagulation at this university in 1979 </plain></SENT>
<SENT sid="2" pm="."><plain>At that time, the head of the laboratory was Marc Verstraete </plain></SENT>
<SENT sid="3" pm="."><plain>Luis had a particular interest in antibody-mediated <z:e sem="disease" ids="C0005779" disease_type="Disease or Syndrome" abbrv="">coagulation disorders</z:e>, and had prepared reviews on <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> induced by <z:chebi fb="5" ids="28304">heparin</z:chebi> [3] and on the <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> inhibitor [4] </plain></SENT>
<SENT sid="4" pm="."><plain>In Leuven, he joined Jos Vermylen, senior member of the laboratory, and an internist with particular interest in hemostasis, <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>As such, Professor Vermylen was involved in both laboratory research and patient care </plain></SENT>
</text></document>